Interferon-alpha inhibits CFU-GM mobilization following chemotherapy and G-CSF administration

J Interferon Cytokine Res. 1996 Nov;16(11):953-6. doi: 10.1089/jir.1996.16.953.

Abstract

Changes in routine hematologic data and in circulating granulocyte-macrophage colony-forming units (CFU-GM) during granulocyte colony-stimulating factor (G-CSF) administration were evaluated in non-small cell lung carcinoma (NSCLC) patients treated with a combination of 5-fluorouracil (5-FU) and cisplatin (DDP) with and without the addition of interferon-alpha (IFN-alpha). The patterns of leukocyte changes following chemotherapy plus G-CSF were similar in both the IFN-alpha-inclusive and the IFN-alpha-devoid courses. However, the twofold increase in CFU-GM observed in patients receiving chemotherapy plus G-CSF was completely absent following the course including IFN-alpha. The activity of G-CSF on the hematologic pattern is seemingly affected by its combination with IFN-alpha treatment. Mechanisms of the possible in vivo interaction among IFNs and hematopoietic growth factors remain to be elucidated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Cisplatin / therapeutic use
  • Evaluation Studies as Topic
  • Fluorouracil / therapeutic use
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Granulocyte-Macrophage Colony-Stimulating Factor / blood*
  • Hematocrit
  • Hematologic Tests
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use
  • Leukocytes / drug effects
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Statistics, Nonparametric

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Cisplatin
  • Fluorouracil